Digital Content 
NEWS #PharmaBuzz
21 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/22/3065080/0/en/HUTCHMED-Completes-Patient-Enrollment-of-a-Phase-II-Registration-Study-of-Savolitinib-in-Gastric-Cancer-in-China.html
19 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/20/3045892/0/en/HUTCHMED-Highlights-Savolitinib-SAVANNAH-Phase-II-and-Other-Data-at-European-Lung-Cancer-Congress-2025.html
13 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/14/3008991/0/en/HUTCHMED-Announces-NMPA-Full-Approval-for-ORPATHYS-savolitinib-in-China-for-Patients-with-Locally-Advanced-or-Metastatic-MET-Exon-14-NSCLC.html
01 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/02/3003295/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-ORPATHYS-and-TAGRISSO-Combination-in-Lung-Cancer-Patients-with-MET-amplification-After-Progression-on-Fir.html
11 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/12/2995863/0/en/HUTCHMED-Announces-Breakthrough-Therapy-Designation-in-China-for-ORPATHYS-and-TAGRISSO-Combination-in-Certain-Lung-Cancer-Patients-After-Disease-Progression-on-EGFR-Inhibitor-Thera.html
28 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/28/2988577/0/en/HUTCHMED-Announces-Continued-Inclusion-of-ORPATHYS-savolitinib-in-the-National-Reimbursement-Drug-List-in-China-at-Current-Terms.html
Share 